NAT2 and urinary bladder cancer: Conversely, the effect of CMR-determined slow acetylation status on bladder cancer risk was greatly increased after controlling for genetic variation in the NAT2, further suggesting hepatic N-acetylation measured by CMR is a detoxification pathway of bladder carcinogen arylamines.